7 Results for "

immunoproteasome β5i subunit

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "immunoproteasome β5i subunit" in MCE Product Catalog:

  • Targets Recommended:
5
5 Cited Publications
Cat. No.: HY-111790
CAS No.: 2285330-15-4
Purity:  ≥98.0%
Target:  

Proteasome Apoptosis

Research Areas:  

Cancer

M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
loading...
    loading...
Cat. No.: HY-148732
CAS No.: 1620107-33-6
Purity:  98.24%
Target:  

Proteasome

Research Areas:  

Inflammation/Immunology

LU-005i is a potent inhibitor of β5i subunit of immunoproteasomes (IC50 = 6.6 nM), selective over β5c subunit (IC50 = 287 nM) .
loading...
    loading...
Cat. No.: HY-142920
CAS No.: 2671040-07-4
Target:  

Proteasome

Research Areas:  

Inflammation/Immunology

LMP7-IN-1, a Boronic acid derivative, is a potent and selective immunoproteasome subunit LMP7 (β5i) inhibitor with an IC50 of 1.83 nM (WO2021143923A1; compound 20) .
loading...
    loading...
Cat. No.: HY-187220
CAS No.: 3119216-05-3
β5i-IN-2 is a potent, selective, and orally active inhibitor of the immunoproteasome β5i subunit, with an IC50 of 0.08 μM against human β5i. β5i-IN-2 inhibits LPS (HY-D1056)- and IFN-γ-induced expression of IL-1β, IL-6, and TNF-α, and suppresses the JNK, ERK, and NF-κB signaling pathways. β5i-IN-2 can be used in research related to rheumatoid arthritis and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-187442
Research Areas:  

Infection Cancer

TDI6245 is a Aurora kinase A (AURKA) inhibitor with an IC50 value of 21.64 nM against AURKA. TDI6245 also inhibits the β5 subunit of the 20S proteasome from Plasmodium falciparum (Pf 20S), with IC50 values of 0.11 μM, 31.1 μM and 6.8 μM against Pf 20S β5, human constitutive proteasome β5c and human immunoproteasome β5i subunits, respectively. TDI6245 binds to the AURKA pocket and the substrate cleft of Pf 20S β5 via antiparallel β-sheets and hydrogen bonds. TDI6245 inhibits the growth of Plasmodium falciparum. TDI6245 can be used in research related to triple-negative breast cancer and malaria .
loading...
    loading...
Cat. No.: HY-111790R
CAS No.: 2285330-15-4
Research Areas:  

Cancer

M3258 (Standard) is the analytical standard of M3258 (HY-111790). This product is intended for research and analytical applications. M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
loading...
    loading...
Cat. No.: HY-183683
CAS No.: 2803611-81-4
Target:  

Proteasome Apoptosis

Research Areas:  

Cancer

DQ-9 is a selective immunoproteasome β5i inhibitor (IC50=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia) .
loading...
    loading...